Patent · US Active

Androgen receptor-dependent gene expression control

US9370499B2 · kind B2 · utility

0Cited by

1References

5Claims

0Family size

Assignee

UNIVERSITAETSKLINIKUM FREIBURG · DE

Inventors

Roland Schuele · Kenzingen, DE
Eric Metzger · Neuf-Brisach, FR

Key dates

Filing date	Feb 4, 2014
Grant date	Jun 21, 2016
Priority date	—
Expiry date	Feb 4, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.